- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Pegozafermin, Placebo
- Drug
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 32
- States / cities
- La Mesa, California • San Francisco, California • Clearwater, Florida + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- NASH
- Interventions
- Pegozafermin, Placebo
- Drug · Other
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 25
- States / cities
- Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Interventions
- Pegozafermin, Placebo
- Biological · Other
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Pegozafermin, Placebo
- Drug
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 65 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- BIO89-100
- Drug
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Chandler, Arizona
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Interventions
- Pegozafermin, Placebo
- Biological · Drug
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 762 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 122 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- BIO89-100, Placebo
- Drug
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 68 more